Company Summary
Beactica Therapeutics is a specialist precision oncology company, founded in 2006 as a spin-out from Uppsala University in Sweden.
With a precise and targeted approach, we bring highly accomplished specialists and our rich history in drug discovery & development together to methodically fulfil urgent needs within the cancer therapeutics industry.
Investing in Beactica offers a compelling opportunity to build wealth in proprietary small molecule cancer therapeutics, building on the company’s established track record and partner-validated drug development technology.
What is Beactica Therapeutics’ legal trading name?
The Company’s legal trading name is Beactica Therapeutics AB
When was Beactica Therapeutics founded?
The Company was founded in 2006 by Dr Per Källblad and Prof. Helena Danielson.
What is Beactica Therapeutics’ listing status?
The Company is privately held.
Where is Beactica Therapeutics’ corporate headquarters?
The Company is headquartered in Uppsala, Sweden. Click here for Company contact information.
Where is Beactica Therapeutics incorporated?
The Company is incorporated in Sweden.
Who is Beactica Therapeutics’ independent auditor/accounting firm?
The Company’s independent auditor is PwC. They have had this role since Beactica was founded in 2006.
Who is Beactica Therapeutics’ legal counsel?
The Company’s legal counsel is Lindahl. Beactica has worked with Lindahl since 2006.
Who is Beactica Therapeutics’ bank?
The Company’s bank is Nordea Bank.
Who is Beactica Therapeutics’ IP advisor?
The Company’s intellectual property (IP) advisor is AWA.
Who makes up Beactica Therapeutics' Management Team and Board of Directors?
Which events will Beactica Therapeutics be attending?
Keep up to date with the events we will be attending on our events page .
Who should I contact regarding investor inquiries?
Please email info@beactica.com for all investor inquiries.
Stay Updated
Sign up for the Beactica newsletter to receive our latest news and updates